Announcement PDF Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 1 ASX ANNOUNCEMENT Actinogen presentsa brief corporate presentationhighlightingthe Company, Xanamem and its strong scientific rationale in Alzheimer’s disease based on human cortisol literature Sydney, 06 August 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce the 12-minute podium presentation entitled “Advancing Oral Xanamem in Alzheimer’s disease” presented at the annual Bioshares Biotech Summit in Queenstown, NZ, today. Highlights from the presentation are: 1. Xanamem® (emestedastat) is a promising, oral enzyme inhibitor designed to control elevated levels of the “stress hormone”, cortisol, in the brain 2. Cortisol is synthesized from inactive cortisonein brain tissueby Xanamem’s target enzyme, 11β-HSD1 3. The rationale for controlling cortisol in Alzheimer’s disease (AD) via inhibition of its production by 11β- HSD1 is strong: a. The adverse effects in the brain of therapeutic cortisol or excess cortisol seen in diseases such as Cushing’s syndrome include impairment of memory, learning and problem-solving, as well as psychiatric symptoms and shrinkage of brain tissue b. Elevated cortisol levels in brain fluid are associated with AD c. Elevated cortisol levels in brain fluid are also associated with the major genetic risk factor for AD, ApoE4 d. Genetic alterations of 11β-HSD1 affect risk of cognitive decline: overexpression leads to decline while absence of expression is protective e. Xanamem has shown preliminary activity in a trial of patients with mild AD and positive effects on attention and working memory in older volunteers. 4. The Company’s first pivotal trial in 247 participants with AD will report topline, final results in November this year. A copy of the presentation is attached to this announcement. View this announcement on our InvestorHub: https://investors.actinogen.com.au/link/eW1apP ENDS ® Xanamem is a registered trademark of Actinogen Medical Limited Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 2 Investors Media Dr Steven Gourlay Michael Roberts George Hazim CEO & Managing Director Communications Media & Public Affairs Australia P: +61 2 8964 7401 M: +61 423 866 231 M: +61 417 516 262 E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au Announcement authorised by the Disclosure Committee of Actinogen Medical Limited About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol.There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health. Cognitive function means how a person understands,remembers and thinks clearly.Cognitive functions include memory, attention, reasoning, awareness and decision-making. Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer’s Disease. It has also conducted a phase 2 trial in patients with cognitive impairmentand depression andmay study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impactin these and many other diseases.The cognitive dysfunction,behavioural abnormalities,and neuropsychological burden associated with these conditions is debilitating for patients,and there is a substantial unmetmedical need for new and improved treatments. Clinical Trials The XanaMIA Phase 2b/3 Alzheimer’s disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 247 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood.Patients receive Xanamem 10 mg or placebo, once daily,and its ability to slow progression of Alzheimer’s disease is assessed with a variety of endpoints.The primary endpointof the trial is the internationally-recognized CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial is being conducted in Australia and the US and is now closed to participant recruitment. It has passed an independent Data Monitoring Committee safety and efficacy futility review and final topline results are expected in November 2026. The XanaMIA-OLE Alzheimer’s disease open-label extension is an open-label phase of up to 25 months treatment where all participants will receive active Xanamem 10 mg once daily. The trial evaluates safety and a limited number of efficacy endpoints such as the CDR-SB. The trial commenced in March 2026 and is open to all former and current participants in the XanaMIA Phase 2b/3 trial. The XanaCIDD Phase 2a depression trial was a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 167 patients with moderate, treatment-resistant depression and a degree of baseline cognitive impairment. Participants were evenly randomized to receive Xanamem 10 mg once daily or placebo, in most cases in addition to their existing antidepressanttherapy,and effects on cognition and depressionwere assessed.Trial results were reported in August 2024 and showed clinically and statistically significantbenefits on depression symptoms with positive effects on the MADRS scale (a validated scale of depression symptom measurement) and the PGI-S (a valid patient reported assessmentof depression severity). Cognition improved markedly and to a similar extent in both Xanamem and placebo groups. The peer-reviewed publication relating to this trial can be accessed for free via this link: https://tinyurl.com/ckm63z63. About Xanamem (emestedastat) Xanamem’s novel mechanism is to control elevated levels of cortisol (aka the “stress hormone”) in the brain through the inhibition of the cortisol synthesis enzyme,11β-HSD1,withoutaffecting production of cortisol by the adrenal glands which is essential for the body’s normal functioning.Xanamem is a first-in-class,once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex. To view Xanamem’s two-minute Mechanism of Action animation, click here. Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 3 Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The recent XanaCIDD trial demonstrated clinically and sometimes statistically significant benefits on depressive symptoms, further validating the cortisol control mechanism for the Xanamem 10 mg oral daily dose. The Company has studied 11β-HSD1 inhibition by Xanamem in more than 500 volunteers and patients in eight clinical trials. Xanamem has a promising safety profile and has demonstrated clinical activity in patients with depression,patients with biomarker-positive Alzheimer’s disease and cognitively normal volunteers. High levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. Xanamem is an investigational productand is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical. Disclaimer This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates,assumptions andqualifications;and relate to circumstances and events thathave nottaken place and may nottake place.Such forward looking statements should be considered “at-risk statements” - notto be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements.You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievementor reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised. ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP. Advancing oral Xanamem® in Alzheimer’s Disease Topline data from phase 2b/3 pivotal trial in November (n=247) Potentially game-changing product profile Strong scientific rationale for brain cortisol as a therapeutic target Corporate Presentation, Bioshares 2026 August 6, 2026 ® Xanamem is a registered trademark of Actinogen Medical Limited 2 This presentation is dated June 2026 and has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. It should be read in conjunction with the Company’s most recent financial report and other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (”ASX”), which are available at www.asx.com.au under the Company’s ticker code (ASX: ACW). This presentation does NOT constitute a “Prospectus” or a “Disclosure Document” (as defined in the Corporations Act 2001 (Cth)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act 2001 (Cth). This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. This presentation is not for general distribution or third party reliance or use. The distribution of this presentation in the United States and elsewhere outside Australia may be restricted by law and you should observe any such restrictions. Any recipient of this presentation who is outside Australia must observe any such restrictions. This presentation has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 (the “US Securities Act”) and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management in respect of which there is NO guarantee of future performance. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends. A number of important factors could cause the Company’s actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward looking statements, including (without limitation) the risks and uncertainties associated with the ongoing impacts of the Australian and global economic environment and capital market conditions and the risk factors described in the slides titled "Summary of key risks", with many of these factors are beyond the Company’s control. To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (Parties) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation. Disclaimer Corporate Presentation Bioshares August 2026 3 Corporate and Xanamem highlights Validated 11β-HSD1 mechanism with differentiated oral profile • Xanamem is a novel oral therapy targeting elevated brain cortisol, a well- established risk factor for Alzheimer’s disease and depression • Oral administration and favorable safety profile support broad use Biomarker-enriched pivotal trial with independent validation • XanaMIA phase 2b/3 pivotal trial (n=247) fully enrolled; open-label extension commenced; topline results November 2026 • January 2026 independent Data Monitoring Committee recommended the trial continue unchanged following unblinded interim review of safety and efficacy futility Regulatory clarity in the US and EU • Current pivotal trial expected to form part of registrational package for Alzheimer’s disease • FDA and EMA guidance support a streamlined marketing approval path requiring only one additional pivotal trial following positive XanaMIA results Corporate Presentation Bioshares August 2026 Potentially game-changing oral therapy in late-stage trials for Alzheimer’s disease Strong capital position • Company funded through mid 2027 • Resources focused on execution of the XanaMIA trial and its extension phase NEXT MAJOR VALUE INFLECTION Pivotal trial topline results November 2026 3 Why do we believe brain cortisol control with Xanamem can slow Alzheimer’s disease (AD)? Corporate Presentation Bioshares August 2026 4 Cortisol and the Alzheimer’s brain “Stress” and/or genetic factors may drive multiple AD mechanisms via cortisol 5 Corporate Presentation Bioshares August 2026 Seckl J 2024 (left panel); Milligan Armstrong et al. 2021 https://doi.org/10.1111/brv.12750 Xanamem’s target: Genetic alternations are both protective (down) and a risk factor (up) for cognitive decline Elevated human brain cortisol levels linked to AD Brain fluid cortisol measurements best reflect the tissue cortisol environment 6 Corporate Presentation Bioshares August 2026 Popp et al, 2015 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 Cognitive Normal MCI Other MCI AD AD dementia CSF cortisol (μg/dl) p<0.001 Popp et al., 2015, Neurobiol. Aging 36:601–607 German Dementia Competency Network study Major AD genetic risk factor of ApoE4 associated with elevated brain cortisol levels ~67% of patients in AD trials have one or two copies of the ApoE4 gene 7 Corporate Presentation Bioshares August 2026 Gil-Bea et al. 2010 a) CSF cortisol level by disease classification (SCI: subjective cognitive impairment; SMCI stable mild cognitive impairment: progressive mild cognitive impairment; AD Alzheimer’s disease b) As above by known ApoE4 genetic status (0 vs. 1-2 copies) Therapeutic cortisol worsened AD over 12 months Historical trial of 10mg prednisolone in patients with mild to moderate disease (n=138) 8 Corporate Presentation Bioshares August 2026 Aisen et al. Neurology 54:Feb 2000; dropouts were more common in the prednisolone group 0 1 2 3 4 5 6 7 8 9 Cognition Dementia Depression Placebo Prednisolone (cortisol) Worsening Point Change In Score ADAS-cog P=0.16 CDR-SB P=0.07 Ham-D P=0.25 Cortisol excess is toxic to the brain Literature from clinical use as a therapeutic and excess cortisol in Cushing’s syndrome Symptom or sign of brain toxicity Trends to worsening Alzheimer’s disease Shrinkage to hippocampus General brain shrinkage Memory impairment Executive function impairment Difficulty learning Poor concentration Anxiety Depression 9 Corporate Presentation Bioshares August 2026 Data reported for Cushing’s syndrome of endogenous excess cortisol and/or therapeutic corticosteroids Dekkers et al. 2022; Liu et al. 2022; De Alcubierre et al. 2023; Katragadda et al. 2025 Xanamem achieves high brain target occupancy Distribution of cortisol synthesis enzyme 11β-HSD1 shown in left panel SUVRcarotid 5 mg Xanamem Baseline After 7 days of daily dosing 10 mg Xanamem 20 mg Xanamem Journal of Alzheimer’s Disease 97 (2024) 1463–1475 Brain 11-Hydroxysteroid Dehydrogenase Type 1 Occupancy by Xanamem Assessed by PET in Alzheimer’s Disease and Cognitively Normal Individuals Victor L. Villemagne, Vincent Dor, Lee Chong, Michael Kassiou, Rachel Mulligan, Azadeh Feizpour, Jack Taylor, Miriam Roesner, Tamara Miller and Christopher C. Rowe Corporate Presentation Bioshares August 2026 Reduction in tracer signal (loss of color) indicates high 11β-HSD1 occupancy - Strong occupancy observed across evaluated clinical doses 10 Xanamem data in patients with mild Alzheimer’s Phase 2a data showed slowing of decline over 12 weeks (n=34 with high pTau181) Corporate Presentation Bioshares August 2026 0.36 0.98 0 0.2 0.4 0.6 0.8 1 1.2 1.4 Baseline Week 12 Xanamem Placebo 0.6-point benefit @12 weeks Xanamem vs. Placebo • Mean 0.6 units • Median 0.8 units • p = 0.09 • Cohen’s d = 0.4 CDR-SB* units Change from Baseline (SE) Worse performance Journal of Alzheimer’s Disease 100 (2024) 139–150 * Clinical Dementia Rating scale – Sum of Boxes Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11-HSD1 Inhibitor Xanamem® for Mild Alzheimer’s Disease Jack Taylor, Mark Jaros, Christopher Chen, John Harrison and Dana Hilt 11 Durable activity in phase 2 depression trial Separation from placebo overall and on background SSRI therapy Corporate Presentation Bioshares August 2026 EOT 2.6-point difference Cohen’s d = 0.38 p = 0.15 PT 4.2-point difference Cohen’s d = 0.64 p = 0.03 Abbreviations: SSRI, selective serotonin reuptake inhibitor. *Planned phase 3 population MADRS LS mean change from baseline (± SE) Xanamem (n=37) Placebo (n=39) ON TREATMENT AND BACKGROUND SSRI THERAPY (n=76)* FOLLOW UP -12 -10 -8 -6 -4 -2 0 Baseline Week 2 Week 4 Week 6 Week 10 12 Better Depression -3 -2.5 -2 -1.5 -1 -0.5 0 0.5 donanemab all placebo all What we hope to see in November: much greater ability to slow disease than existing treatments Xanamem phase 2a p- tau–positive patients showed near- stabilization Worsening of CDR-SB over 18 months Worse performance Modest benefit of donanemab (Kisunla) over 18 months1 1. Sims et al. JAMA 2023 336(6):512-527 Corporate Presentation Bioshares August 2026 Xanamem may stabilize or slow CDR-SB progression more than other therapies SIMULATED PHASE 2B/3 DATA 13 14 Contacts Will Souter CFO & Investor Relations M: +61 402 035 716 E. will.souter@actinogen.com.au Steven Gourlay CEO & Managing Director P: +61 2 8964 7401 E. steven.gourlay@actinogen.com.au Join the Actinogen Investor Hub: https://investors.actinogen.com.au/ Corporate Presentation Bioshares August 2026 14